1. Men whose partner plans to become pregnant within 12 months from the screening period to the full immunization, 2. Those with a history of new coronavirus vaccination, 3. Those who have been diagnosed with new coronavirus pneumonia cases or suspected cases, have a history of contact with confirmed or suspected cases of new coronavirus within 1 month before signing the informed consent form, or have travel experience in high-risk areas or overseas, or new coronavirus Infected person or carrier: positive for anti-SARS-CoV-2 specific antibody in serum, or positive for SARS-CoV-2 nucleic acid in throat swab specimen, 4. Persons with positive tests for hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum specific antibody, and human immunodeficiency virus antibody, 5. There is a history of SARS, MERS and other coronavirus infection or disease history, 6. Those with acute disease or acute exacerbation of chronic disease within 7 days before the first dose of vaccine, or fever (armpit temperature = 37.3?) or symptoms of upper respiratory tract infection within 3 days before the first dose of vaccine, 7. Have any history of serious adverse reactions to vaccines or drugs, such as: allergy, urticaria, skin eczema, dyspnea, angioedema, etc., 8. Have received any vaccine within 1 month before the first dose of vaccine, 9. Those who cannot tolerate venous blood collection, and those who have a history of fainting with needles and haemorrhage, 10. Has hereditary bleeding tendency or coagulation dysfunction, or has a history of thrombosis or hemorrhage, and the test results of coagulation function-related indicators are abnormal, 11. Has been diagnosed with congenital or acquired immunodeficiency (eg: HIV infection), 12. Asplenia, functional asplenia, and surgical removal of other vital organs for any reason, 13. Previous serious diseases with abnormal clinical manifestations that need to be excluded, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system and history of malignant tumors, excluding history of stable chronic diseases, such as diabetes, hypertension, etc., 14. Those who have undergone surgery within 3 months before signing the informed consent form, or those who plan to undergo surgery during the trial, 15. Have used any investigational or unregistered products (drugs, vaccines, biological products or devices) other than this research vaccine within 3 months before signing the informed consent, or plan to use it during the study, 16. Individuals who have used any investigational or unlicensed products (drugs, vaccines, biological products or devices) other than investigational vaccines within 3 months prior to signing the informed consent form, or plan to use the above-mentioned products during the study period, 17. Received immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term application of systemic glucocorticoid therapy (systemic glucocorticoid therapy for more than 2 consecutive weeks within 6 months, such as prednisone or similar drugs ), but topical application (such as ointment, eye drops, inhaler or nasal spray) is allowed, and topical application should not exceed the dose recommended in the instructions or have any signs of systemic exposure, 18. There are other circumstances that t

1. Men whose partner plans to become pregnant within 12 months from the screening period to the full immunization, 2. Those with a history of new coronavirus vaccination, 3. Those who have been diagnosed with new coronavirus pneumonia cases or suspected cases, have a history of contact with confirmed or suspected cases of new coronavirus within 1 month before signing the informed consent form, or have travel experience in high-risk areas or overseas, or new coronavirus Infected person or carrier: positive for anti-SARS-CoV-2 specific antibody in serum, or positive for SARS-CoV-2 nucleic acid in throat swab specimen, 4. Persons with positive tests for hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum specific antibody, and human immunodeficiency virus antibody, 5. There is a history of SARS, MERS and other coronavirus infection or disease history, 6. Those with acute disease or acute exacerbation of chronic disease within 7 days before the first dose of vaccine, or fever (armpit temperature = 37.3?) or symptoms of upper respiratory tract infection within 3 days before the first dose of vaccine, 7. Have any history of serious adverse reactions to vaccines or drugs, such as: allergy, urticaria, skin eczema, dyspnea, angioedema, etc., 8. Have received any vaccine within 1 month before the first dose of vaccine, 9. Those who cannot tolerate venous blood collection, and those who have a history of fainting with needles and haemorrhage, 10. Has hereditary bleeding tendency or coagulation dysfunction, or has a history of thrombosis or hemorrhage, and the test results of coagulation function-related indicators are abnormal, 11. Has been diagnosed with congenital or acquired immunodeficiency (eg: HIV infection), 12. Asplenia, functional asplenia, and surgical removal of other vital organs for any reason, 13. Previous serious diseases with abnormal clinical manifestations that need to be excluded, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system and history of malignant tumors, excluding history of stable chronic diseases, such as diabetes, hypertension, etc., 14. Those who have undergone surgery within 3 months before signing the informed consent form, or those who plan to undergo surgery during the trial, 15. Have used any investigational or unregistered products (drugs, vaccines, biological products or devices) other than this research vaccine within 3 months before signing the informed consent, or plan to use it during the study, 16. Individuals who have used any investigational or unlicensed products (drugs, vaccines, biological products or devices) other than investigational vaccines within 3 months prior to signing the informed consent form, or plan to use the above-mentioned products during the study period, 17. Received immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term application of systemic glucocorticoid therapy (systemic glucocorticoid therapy for more than 2 consecutive weeks within 6 months, such as prednisone or similar drugs ), but topical application (such as ointment, eye drops, inhaler or nasal spray) is allowed, and topical application should not exceed the dose recommended in the instructions or have any signs of systemic exposure, 18. There are other circumstances that t

1. Individuals whose results from a complete physical examination do not meet the health standards, mainly include: 1) Abnormal vital signs with clinical significance (pulse < 50 times/min or > 100 times/min, systolic blood pressure >=140 mmHg or diastolic blood pressure >=90 mmHg an a conscious adult), 2) BMI <18 kg/m2 or >30 kg/m2, 3) In the screening window, the laboratory test value exceeds 1.2 ULN, and is determined by the investigator to be clinically significant, 2. Male subjects whose partners plan to become pregnant from screening to 12 months after complete series, 3. Individuals with history of vaccination with COVID-19 vaccines, 4. Individuals with prior diagnosis as COVID-19 cases or suspected cases. Individuals who have a history of contact with COVID-19 cases or suspected cases within 1 month before signing the informed consent, or those who have overseas travel history or have traveled to areas with high incidence of COVID-19, COVID-19 infectors or carriers: those with positive results for serum SARS-CoV-2-specific antibodies or SARS-CoV-2 nucleic acid in throat swabs, 5. Individuals who are tested positive for hepatitis B surface antigen, hepatitis C virus antibody, treponema pallidum-specific antibody and human immunodeficiency virus antibody, 6.Individuals who have a history of infections or diseases caused by SARS, MERS or other coronavirus, 7. Individuals who have acute diseases or acute attack of chronic diseases within 7 days prior to the first dose, or have fever (axillary temperature >=37.3 degree C) or upper respiratory tract infection within 3 days prior to the first dose, 8.Individuals who have a history of severe side effects induced by any vaccine or drug, such as allergy, urticaria, eczema, dyspnea, angioneurotic edema, etc., 9. Individuals who have been vaccinated with any vaccine within 1 month prior to the first dose, 10. Individuals who cannot tolerate the venipuncture and who have fainting history during acupuncture or at the sight of blood, 11. Individuals who have hereditary bleeding tendency or coagulation dysfunction, or have history of thrombosis or bleeding, and those with abnormal detection results of coagulation-related measurements, 12. Individuals who have been diagnosed with congenital or acquired immunodeficiency (e.g., HIV infection), 13. Individuals who have asplenia or functional asplenia, or have other important organs removed by surgery for any reason, 14. Individuals who previously have serious diseases with abnormal clinical manifestations that needed to be excluded, including, but not limited to history of systemic diseases and malignant tumors for nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system, excluding stable chronic diseases, such as diabetes, hypertension, etc., 15. Individuals who have undergone any surgeries within 3 months prior to the signing of informed consent, or plan to have any surgeries during the trial period, 16. Individuals who had blood donation or blood loss (>=450 mL), blood transfusion or use of blood products within 3 months prior to the signing of the informed consent, or plan to donate blood during the trial period, 17. Individuals who used any investigational or unlicensed products (drug, vaccine, biological product or device) other than the study vaccine within 3 months prior to the signing of the informed consent

1. Individuals whose results from a complete physical examination do not meet the health standards, mainly include: 1) Abnormal vital signs with clinical significance (pulse < 50 times/min or > 100 times/min, systolic blood pressure >=140 mmHg or diastolic blood pressure >=90 mmHg an a conscious adult), 2) BMI <18 kg/m2 or >30 kg/m2, 3) In the screening window, the laboratory test value exceeds 1.2 ULN, and is determined by the investigator to be clinically significant, 2. Male subjects whose partners plan to become pregnant from screening to 12 months after complete series, 3. Individuals with history of vaccination with COVID-19 vaccines, 4. Individuals with prior diagnosis as COVID-19 cases or suspected cases. Individuals who have a history of contact with COVID-19 cases or suspected cases within 1 month before signing the informed consent, or those who have overseas travel history or have traveled to areas with high incidence of COVID-19, COVID-19 infectors or carriers: those with positive results for serum SARS-CoV-2-specific antibodies or SARS-CoV-2 nucleic acid in throat swabs, 5. Individuals who are tested positive for hepatitis B surface antigen, hepatitis C virus antibody, treponema pallidum-specific antibody and human immunodeficiency virus antibody, 6.Individuals who have a history of infections or diseases caused by SARS, MERS or other coronavirus, 7. Individuals who have acute diseases or acute attack of chronic diseases within 7 days prior to the first dose, or have fever (axillary temperature >=37.3 degree C) or upper respiratory tract infection within 3 days prior to the first dose, 8.Individuals who have a history of severe side effects induced by any vaccine or drug, such as allergy, urticaria, eczema, dyspnea, angioneurotic edema, etc., 9. Individuals who have been vaccinated with any vaccine within 1 month prior to the first dose, 10. Individuals who cannot tolerate the venipuncture and who have fainting history during acupuncture or at the sight of blood, 11. Individuals who have hereditary bleeding tendency or coagulation dysfunction, or have history of thrombosis or bleeding, and those with abnormal detection results of coagulation-related measurements, 12. Individuals who have been diagnosed with congenital or acquired immunodeficiency (e.g., HIV infection), 13. Individuals who have asplenia or functional asplenia, or have other important organs removed by surgery for any reason, 14. Individuals who previously have serious diseases with abnormal clinical manifestations that needed to be excluded, including, but not limited to history of systemic diseases and malignant tumors for nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system, excluding stable chronic diseases, such as diabetes, hypertension, etc., 15. Individuals who have undergone any surgeries within 3 months prior to the signing of informed consent, or plan to have any surgeries during the trial period, 16. Individuals who had blood donation or blood loss (>=450 mL), blood transfusion or use of blood products within 3 months prior to the signing of the informed consent, or plan to donate blood during the trial period, 17. Individuals who used any investigational or unlicensed products (drug, vaccine, biological product or device) other than the study vaccine within 3 months prior to the signing of the informed consent